Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2005-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-04-0287PMID 16170022
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SRCircumventing imatinib resistance.

  2004cited by this paper
• The Mechanism of the Anti-Tumor Activity of the Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA)

  2004cited by this paper
• Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line

  2004cited by this paper
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

  2004cited by this paper
• Roles of Gab1 and SHP2 in Paxillin Tyrosine Dephosphorylation and Src Activation in Response to Epidermal Growth Factor*

  2004cited by this paper
• Molecular determinants of resistance to antiandrogen therapy

  2004influential reference
• Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824

  2004cited by this paper
• The biology and clinical relevance of the PTEN tumor suppressor pathway.

  2004cited by this paper
• Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

  2003cited by this paper
• Acetylation of Androgen Receptor Enhances Coactivator Binding and Promotes Prostate Cancer Cell Growth

  2003cited by this paper
• N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

  2003cited by this paper
• The embedded tumour: host physiology is important for the evaluation of tumour growth

  2003cited by this paper
• A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

  2003cited by this paper
• Heat shock protein 90

  2003cited by this paper
• Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery 1

  2003cited by this paper
• Human epidermal receptor-2 expression in prostate cancer.

  2003cited by this paper
• NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

  2003cited by this paper
• Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.

  2003cited by this paper
• The discovery of NVP-LAQ824: from concept to clinic.

  2003cited by this paper
• Hsp90 as a therapeutic target in prostate cancer.

  2003cited by this paper
• Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.

  2003cited by this paper
• Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.

  2003cited by this paper
• Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer.

  2003cited by this paper
• Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.

  2002cited by this paper
• Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.

  2002cited by this paper
• 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

  2002cited by this paper
• Functional analysis of 44 mutant androgen receptors from human prostate cancer.

  2002cited by this paper
• Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.

  2002cited by this paper
• Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor

  2002cited by this paper
• Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.

  2002cited by this paper
• Effect of geldanamycin on androgen receptor function and stability

  2002cited by this paper
• Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10*

  2002cited by this paper
• Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.

  2001cited by this paper
• Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1

  2001cited by this paper
• Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.

  2001cited by this paper
• Androgen receptor signaling in androgen-refractory prostate cancer.

  2001influential reference
• Histone deacetylases and cancer: causes and therapies

  2001cited by this paper
• Her-2-neu expression and progression toward androgen independence in human prostate cancer.

  2000cited by this paper
• Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

  2000influential reference
• Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides

  2000cited by this paper
• The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells.

  2000cited by this paper
• HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.

  2000cited by this paper
• A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

  1999cited by this paper
• Expression, structure, and function of androgen receptor in advanced prostatic carcinoma

  1998cited by this paper
• Role of Tyrosine Kinase Activity of Epidermal Growth Factor Receptor in the Lysophosphatidic Acid-stimulated Mitogen-activated Protein Kinase Pathway*

  1998cited by this paper
• Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice

  1997cited by this paper
• Hsp90 Regulates Androgen Receptor Hormone Binding Affinity in Vivo*

  1996cited by this paper
• Derivation of androgen‐independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells

  1994cited by this paper
• Rapid deactivation of MAP kinase in PC12 cells occurs independently of induction of phosphatase MKP‐1

  1994cited by this paper
• Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.

  1994cited by this paper

• Targeting epigenetic effects of androgen-androgen receptor signaling in prostate cancer.

  2025cites this paper
• Advances in dual-targeting inhibitors of HDAC6 for cancer treatment.

  2024cites this paper
• Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer

  2023cites this paper
• The epigenetic function of androgen receptor in prostate cancer progression

  2023cites this paper
• Hybrid Histone Deacetylase Inhibitor: an Effective Strategy for Cancer Therapy.

  2022cites this paper
• HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer

  2022cites this paper
• Epigenetic Coregulation of Androgen Receptor Signaling.

  2022cites this paper
• Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer

  2021cites this paper
• Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment

  2021cites this paper
• Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development

  2020cites this paper
• Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders.

  2020cites this paper
• Recent Studies on HDAC Inhibitors Acting against Prostate Cancer

  2020cites this paper
• The application of the improved 3D rat testicular cells co-culture model on the in vitro toxicity research of HZ1006

  2019cites this paper
• Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage

  2019influential citation
• Histone Deacetylase Inhibitors in Cancer Therapy.

  2019cites this paper
• The application of the improved 3 D rat testicular cells co-culture model on the in vitro toxicity research of HZ 1006

  2018cites this paper
• Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer

  2018cites this paper
• The Role of Alcohol-Induced Golgi Fragmentation for Androgen Receptor Signaling in Prostate Cancer

  2018cites this paper
• Androgen receptor and soy isoflavones in prostate cancer.

  2018cites this paper
• Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A

  2018cites this paper
• Androgen receptor and soy isoflavones in prostate cancer ( Review )

  2018cites this paper
• New Mechanism Based Approaches For Treating Prostate Cancer

  2017influential citation
• Downregulation of androgen receptors by NaAsO2 via inhibition of AKT‐NF‐κB and HSP90 in castration resistant prostate cancer

  2017cites this paper
• Epigenetic polypharmacology: from combination therapy to multitargeted drugs

  2016cites this paper
• Design And Synthesis Of Enzalutamide-Isothiocyanate Hybrid Drug As Anti-Prostate Cancer Agent

  2016cites this paper
• A Review of Therapeutic Ablation Modalities

  2016cites this paper
• Effects of Brassicaceae Isothiocyanates on Prostate Cancer

  2016cites this paper
• Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease HSP90 and the Androgen Receptor Levels and Inhibit Viability in Enzalutamide Resistant C4-2 Prostate Cancer Cells

  2016influential citation
• Can post-transcription modifiers change the course of prostate cancer?

  2016cites this paper
• Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells

  2016influential citation
• Epigenetic-based therapy: From single- to multi-target approaches.

  2015cites this paper
• Combinatorial targeting of the androgen receptor for prostate cancer therapy

  2015cites this paper
• Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials

  2015influential citation
• Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications

  2014cites this paper
• The association between Histone 3 Lysine 27 Trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters

  2014cites this paper
• The association between Histone 3 Lysine 27 Trimethylation ( H 3 K 27 me 3 ) and Prostate Cancer : Relationship with Clinicopathological

  2014cites this paper
• Targeting the androgen receptor in prostate cancer

  2014cites this paper
• Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells

  2014cites this paper
• chaperone function in human leukemia cells HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90

  2013cites this paper
• Ligand-independent androgen receptor antagonism caused by the newly developed pesticide pyrifluquinazon (PFQ).

  2013cites this paper
• Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

  2013cites this paper
• HDAC6 Regulation of Androgen Signaling in Prostate Cancer

  2013cites this paper
• Targeting heat shock proteins in cancer.

  2013cites this paper
• Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

  2012cites this paper
• Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

  2012cites this paper
• Combination Therapy of Antiandrogen and XIAP Inhibitor for Treating Advanced Prostate Cancer

  2012cites this paper
• Tyrosines 303/343/353 within the Sprouty-related domain of Spred2 are essential for its interaction with p85 and inhibitory effect on Ras/ERK activation.

  2012cites this paper
• Nanotherapies for treating prostate cancer

  2012cites this paper
• Novel molecular targets for the therapy of castration-resistant prostate cancer.

  2012cites this paper
• Epigenetics in Prostate Cancer

  2011cites this paper
• Developing histone deacetylase inhibitors as anti-cancer therapeutics.

  2011cites this paper
• New Insights into the Androgen-Targeted Therapies and Epigenetic Therapies in Prostate Cancer

  2011cites this paper
• Emerging Therapies in Castrate-Resistant Prostate Cancer

  2010cites this paper
• Prostate cancer chemopreventive activity of phenethyl isothiocyanate through epigenetic regulation (review).

  2010cites this paper
• Androgen Receptor Signalling in Prostate Cancer: The Functional Consequences of Acetylation

  2010cites this paper
• A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

  2010cites this paper
• Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor

  2010cites this paper
• Epigenetic regulation of androgen receptor signaling in prostate cancer

  2010cites this paper
• The Mechanism of Androgen Deprivation and the Androgen Receptor

  2010cites this paper
• Androgen receptor modulation by non-androgenic factors and the basal transcription factor TAF1

  2010cites this paper
• In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors

  2009cites this paper
• Histone deacetylase inhibitors: Potential in cancer therapy

  2009cites this paper
• Finding the place of histone deacetylase inhibitors in prostate cancer therapy

  2009cites this paper
• Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.

  2009cites this paper
• Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6

  2009cites this paper
• Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.

  2009cites this paper
• Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion.

  2008cites this paper
• KD 5170 , a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo

  2008cites this paper
• Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function

  2008influential citation
• HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.

  2008cites this paper
• Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors.

  2008cites this paper
• Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.

  2008cites this paper
• Anti-apoptotic and Pro-inflammatory Signaling in Cancer Cells: Status and Modulation by Chemotherapeutic Drugs

  2008cites this paper
• Targeted Therapy in Prostate Cancer

  2008cites this paper
• Characterisation of a dominant negative androgen receptor in prostate cancer cells.

  2008cites this paper
• The role of histone deacetylases in prostate cancer

  2008cites this paper
• Down-regulation of androgen-receptor and PSA by phytochemicals.

  2008cites this paper
• Signal Transduction by the Ras–MAP Kinase Pathway in Prostate Cancer Progression

  2008cites this paper
• Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.

  2008cites this paper
• Androgen receptor acetylation sites differentially regulate gene control

  2008cites this paper
• KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo

  2008cites this paper
• In vivo Knockdown of theAndrogen Receptor Results in Growth Inhibition and Regression of Well-Established , Castration-Resistant ProstateTumors

  2008cites this paper
• Targeting the androgen receptor pathway in prostate cancer.

  2008cites this paper
• Posttranscription Regulation of Prostate Cancer Growth

  2008cites this paper
• HDAC 6 inhibition enhances 17-AAG – mediated abrogation of hsp 90 chaperone function in human leukemia cells

  2008cites this paper
• IFI 16 in Human Prostate Cancer

  2007cites this paper
• IFI16 in Human Prostate Cancer

  2007cites this paper
• Differentiation Agents and Epigenomic Therapies

  2007cites this paper
• First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents.

  2007cites this paper
• Histone deacetylases: target enzymes for cancer therapy

  2007cites this paper
• Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins.

  2007cites this paper
• Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase

  2007cites this paper
• Possible effects of early treatments of hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs.

  2007cites this paper
• A new era in prostate cancer therapy: new targets and novel therapeutics

  2007cites this paper
• The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer.

  2007cites this paper
• Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.

  2007cites this paper
• Post-translational modification of heat-shock protein 90: impact on chaperone function

  2007cites this paper
• Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directions.

  2007cites this paper
• Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation

  2007cites this paper
• Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma

  2007cites this paper